Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Chinese Patent Office
Johnson and Johnson
Boehringer Ingelheim
Fish and Richardson

Generated: June 26, 2017

DrugPatentWatch Database Preview

AMELUZ Drug Profile

« Back to Dashboard

What is the patent landscape for Ameluz, and what generic Ameluz alternatives are available?

Ameluz is a drug marketed by Biofrontera and is included in one NDA. There is one patent protecting this drug.

This drug has twelve patent family members in eleven countries.

The generic ingredient in AMELUZ is aminolevulinic acid hydrochloride. There are six drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the aminolevulinic acid hydrochloride profile page.

Summary for Tradename: AMELUZ

Suppliers / Packagers: see list1
Bulk Api Vendors: see list86
Clinical Trials: see list8
Patent Applications: see list141
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:AMELUZ at DailyMed

Pharmacology for Tradename: AMELUZ

Drug ClassPorphyrin Precursor
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
aminolevulinic acid hydrochloride
GEL;TOPICAL208081-001May 10, 2016RXYesYes6,559,183► SubscribeY ► Subscribe
aminolevulinic acid hydrochloride
GEL;TOPICAL208081-001May 10, 2016RXYesYes► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: AMELUZ

Country Document Number Estimated Expiration
Australia758098► Subscribe
Germany19852245► Subscribe
Canada2351620► Subscribe
New Zealand511351► Subscribe
Australia1271000► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Federal Trade Commission
Daiichi Sankyo
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:

Google Plus